Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation (ARISTOPHANES)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03087487|
Recruitment Status : Active, not recruiting
First Posted : March 22, 2017
Last Update Posted : February 9, 2022
|Condition or disease|
|Non-Valvular Atrial Fibrillation|
|Study Type :||Observational|
|Actual Enrollment :||434046 participants|
|Official Title:||Real-World Comparative Effectiveness Research and Related Economic Outcomes Among Nonvalvular Atrial Fibrillation Patients Using Oral Anti-coagulants|
|Actual Study Start Date :||January 1, 2012|
|Actual Primary Completion Date :||September 30, 2015|
|Estimated Study Completion Date :||September 30, 2022|
NVAF patients on Warfarin
NVAF patients newly initiated with Warfarin. Non-Interventional.
NVAF patients on Apixaban
NVAF patients newly initiated on Apixaban. Non-Interventional.
NVAF patients on Dabigatran
NVAF patients newly initiated with Dabigatran. Non-Interventional.
NVAF patients on Rivaroxaban
NVAF patients newly initiated with Rivaroxaban. Non-Interventional.
- Time to first major bleeding event [ Time Frame: Up to 33 months ]
- Time to first stroke/systemic embolism (SE) event [ Time Frame: Up to 33 months ]
- Major bleeding-related medical costs [ Time Frame: Up to 33 months ]
- Stroke/SE-related medical costs [ Time Frame: Up to 33 months ]
- All-cause Healthcare costs [ Time Frame: Up to 33 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03087487
|United States, Michigan|
|Ann Arbor, Michigan, United States, 48104|
|Study Director:||Bristol-Myers Squibb||Bristol-Myers Squibb|